Steroid 5α-Reductase 2 Deficiency Leads to Reduced Dominance-Related and Impulse-Control Behaviors

    February 2018 in “ Psychoneuroendocrinology ”
    Laura J. Mosher, Sean C. Godar, Marc Morissette … Marco Bortolato
    Studysummary This study found that male 5α-reductase 2 knockout mice showed deficits in social dominance behaviors and reduced dopamine receptor binding in a brain region related to social ranking.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on europepmc.org →
    Discuss this study in the Community →

    Research cited in this study 10

    1. Allopregnanolone Mediates the Exacerbation of Tourette-Like Responses by Acute Stress in Mouse Models Scientific reports · 2017
    2. The Neurosteroidogenic Enzyme 5α-Reductase Mediates Psychotic-Like Complications of Sleep Deprivation Neuropsychopharmacology · 2017
    3. Exploring the Neural Mechanisms of Finasteride: A Proteomic Analysis in the Nucleus Accumbens Psychoneuroendocrinology · 2016
    4. Targeting Neurosteroid Synthesis as a Therapy for Schizophrenia-Related Alterations Induced by Early Psychosocial Stress Schizophrenia Research · 2015
    5. Inhibition Of 5α-Reductase Attenuates Behavioral Effects Of D1-, But Not D2-Like Receptor Agonists In C57BL/6 Mice Psychoneuroendocrinology · 2012
    6. Finasteride Attenuates Pathological Gambling in Patients With Parkinson's Disease Journal of Clinical Psychopharmacology · 2012
    7. Inhibition of 5α-Reductase in the Nucleus Accumbens Counters Sensorimotor Gating Deficits Induced by Dopaminergic Activation Psychoneuroendocrinology · 2011
    8. Isolation Rearing-Induced Reduction of Brain 5α-Reductase Expression: Relevance to Dopaminergic Impairments Neuropharmacology · 2011
    9. Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders Current Pharmaceutical Design · 2011
    10. Antipsychotic-Like Properties of 5-Alpha-Reductase Inhibitors Neuropsychopharmacology · 2008